Recombinant SARS-CoV-2 Spike (Sotrovimab Biosimilar) antibody

Catalog No. ABIN7795140

The Human Monoclonal anti-SARS-CoV-2 Spike (Sotrovimab Biosimilar) antibody is suitable to detect SARS-CoV-2 Spike (Sotrovimab Biosimilar) in samples from Human. It has been validated for FACS and in vivo.

Quick Overview for Recombinant SARS-CoV-2 Spike (Sotrovimab Biosimilar) antibody (ABIN7795140)

Target: SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Spike (Sotrovimab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-SARS-CoV-2 Spike (Sotrovimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Characteristics: What is sotrovimab biosimilar research grade? Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. sotrovimab is a human monoclonal antibody (IgG1κ isotype). sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Target: SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Alternative Name: Sotrovimab Biosimilar

Target Type: Biosimilar